# Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias

> **NCT01396499** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 16 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** BKM120

## Key facts

- **NCT ID:** NCT01396499
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2016-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01396499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01396499, "Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01396499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*